GLP1R and cardiovascular disorder: Although GLP-1 receptor agonists are recommended based on efficacy, better side effect profiles, and demonstrated cardiovascular benefit, some reports indicate that these are prescribed in <6% of people with T2D, even those with established cardiovascular disease [20,21].